Mendor/Novartis collaborate on Type 2 diabetes
Mendor, a specialist in the design and development of advanced diabetes management products, is to collaborate with the Finnish subsidiary of pharmaceuticals giant, Novartis, in a pilot project aimed at developing more tailored treatment of Type 2 diabetes.
Twelve clinics and 500 Finnish patients with Type 2 diabetes will take part in the project. All patients will receive instructions on timing their blood glucose measurements based on their individual daily routines; while medical staff will be provided with an overview of how participants’ blood glucose levels vary to enable them to weigh the different treatment options.
|Mendor recently launched an easy-to-use, all-in-one blood glucose meter and Web-based application to help people manage their diabetes more effectively. Photo courtesy of Mendor.
Mendor’s recently launched Discreet™ blood glucose meter has received high praise from clinicians and diabetes specialists worldwide. The meter contains everything needed for daily blood glucose measurements – meter, test strips, and a lancing device – in an integrated package no larger than a typical mobile phone.
Mendor was selected earlier this year as a Red Herring Top 100 Europe Tech Startup.
“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “We believe Mendor embodies the vision, drive and innovation that define a successful entrepreneurial venture.”
For more on Mendor, see our article or the company’s Web site.